Patient preferences in the treatment of alopecia areata: A review of the literature

Adults and adolescents with severe alopecia areata are willing to take significant health risks for a better chance of hair regrowth.

JAK inhibitors effectively improve hair regrowth in alopecia areata with an acceptable safety profile.

Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Oral JAK inhibitors are effective and safe for treating alopecia areata but may need ongoing use to keep results.

Patients with alopecia areata feel less regret about treatment decisions when they are involved in the decision-making process.

Researchers created a new tool to measure the effects of alopecia areata from the patient's view, focusing on hair loss, daily life, and emotional health.

There are no FDA-approved treatments for Alopecia Areata, and current options have varying success and relapse rates.